Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

This trial is studying a combination of two cancer drugs — cabozantinib and nivolumab — specifically in older adults with kidney cancer (renal cell carcinoma). While these drugs are already approved, less is known about how well they work and how well they are tolerated in patients aged 65 and older. **You may be eligible if...** - You are 65 years or older - You have been diagnosed with renal cell carcinoma (kidney cancer) - Your cancer is at an advanced stage or has spread to other parts of the body - You have not received certain prior treatments, or your cancer has progressed on prior therapy **You may NOT be eligible if...** - You have active autoimmune disease requiring steroids or immunosuppressants - You have significant heart, liver, or kidney problems - You have uncontrolled high blood pressure - You have had prior treatment with certain checkpoint inhibitor drugs - You are on blood thinners and have a high bleeding risk Talk to your doctor to see if this trial is right for you.